RGLS vs. ALIM, LXRX, AGEN, XOMA, VNDA, EBS, CDXS, ACHV, RIGL, and SGMO
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Alimera Sciences (ALIM), Lexicon Pharmaceuticals (LXRX), Agenus (AGEN), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector.
Regulus Therapeutics (NASDAQ:RGLS) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by company insiders. Comparatively, 31.4% of Alimera Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Regulus Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -23.74%. Alimera Sciences' return on equity of -53.49% beat Regulus Therapeutics' return on equity.
In the previous week, Regulus Therapeutics and Regulus Therapeutics both had 3 articles in the media. Alimera Sciences' average media sentiment score of 1.58 beat Regulus Therapeutics' score of 1.30 indicating that Alimera Sciences is being referred to more favorably in the news media.
Alimera Sciences has higher revenue and earnings than Regulus Therapeutics. Alimera Sciences is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics received 125 more outperform votes than Alimera Sciences when rated by MarketBeat users. Likewise, 63.54% of users gave Regulus Therapeutics an outperform vote while only 57.70% of users gave Alimera Sciences an outperform vote.
Regulus Therapeutics currently has a consensus target price of $7.25, indicating a potential upside of 216.59%. Alimera Sciences has a consensus target price of $8.00, indicating a potential upside of 162.30%. Given Regulus Therapeutics' higher probable upside, equities research analysts clearly believe Regulus Therapeutics is more favorable than Alimera Sciences.
Regulus Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Summary
Regulus Therapeutics and Alimera Sciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
